• Je něco špatně v tomto záznamu ?

Digital biomarkers and sex impacts in Alzheimer's disease management - potential utility for innovative 3P medicine approach

RL. Harms, A. Ferrari, IB. Meier, J. Martinkova, E. Santus, N. Marino, D. Cirillo, S. Mellino, S. Catuara Solarz, I. Tarnanas, C. Szoeke, J. Hort, A. Valencia, MT. Ferretti, A. Seixas, A. Santuccione Chadha

. 2022 ; 13 (2) : 299-313. [pub] 20220606

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017015

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices. Their use has revolutionized clinical research by enabling high-frequency, longitudinal, and sensitive measurements. In the field of neurodegenerative diseases, an example of a digital biomarker-based technology is instrumental activities of daily living (iADL) digital medical application, a predictive biomarker of conversion from mild cognitive impairment (MCI) due to Alzheimer's disease (AD) to dementia due to AD in individuals aged 55 + . Digital biomarkers show promise to transform clinical practice. Nevertheless, their use may be affected by variables such as demographics, genetics, and phenotype. Among these factors, sex is particularly important in Alzheimer's, where men and women present with different symptoms and progression patterns that impact diagnosis. In this study, we explore sex differences in Altoida's digital medical application in a sample of 568 subjects consisting of a clinical dataset (MCI and dementia due to AD) and a healthy population. We found that a biological sex-classifier, built on digital biomarker features captured using Altoida's application, achieved a 75% ROC-AUC (receiver operating characteristic - area under curve) performance in predicting biological sex in healthy individuals, indicating significant differences in neurocognitive performance signatures between males and females. The performance dropped when we applied this classifier to more advanced stages on the AD continuum, including MCI and dementia, suggesting that sex differences might be disease-stage dependent. Our results indicate that neurocognitive performance signatures built on data from digital biomarker features are different between men and women. These results stress the need to integrate traditional approaches to dementia research with digital biomarker technologies and personalized medicine perspectives to achieve more precise predictive diagnostics, targeted prevention, and customized treatment of cognitive decline.Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-022-00284-3.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017015
003      
CZ-PrNML
005      
20220720100054.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13167-022-00284-3 $2 doi
035    __
$a (PubMed)35719134
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Harms, Robbert L $u Altoida Inc., Houston, TX USA
245    10
$a Digital biomarkers and sex impacts in Alzheimer's disease management - potential utility for innovative 3P medicine approach / $c RL. Harms, A. Ferrari, IB. Meier, J. Martinkova, E. Santus, N. Marino, D. Cirillo, S. Mellino, S. Catuara Solarz, I. Tarnanas, C. Szoeke, J. Hort, A. Valencia, MT. Ferretti, A. Seixas, A. Santuccione Chadha
520    9_
$a Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices. Their use has revolutionized clinical research by enabling high-frequency, longitudinal, and sensitive measurements. In the field of neurodegenerative diseases, an example of a digital biomarker-based technology is instrumental activities of daily living (iADL) digital medical application, a predictive biomarker of conversion from mild cognitive impairment (MCI) due to Alzheimer's disease (AD) to dementia due to AD in individuals aged 55 + . Digital biomarkers show promise to transform clinical practice. Nevertheless, their use may be affected by variables such as demographics, genetics, and phenotype. Among these factors, sex is particularly important in Alzheimer's, where men and women present with different symptoms and progression patterns that impact diagnosis. In this study, we explore sex differences in Altoida's digital medical application in a sample of 568 subjects consisting of a clinical dataset (MCI and dementia due to AD) and a healthy population. We found that a biological sex-classifier, built on digital biomarker features captured using Altoida's application, achieved a 75% ROC-AUC (receiver operating characteristic - area under curve) performance in predicting biological sex in healthy individuals, indicating significant differences in neurocognitive performance signatures between males and females. The performance dropped when we applied this classifier to more advanced stages on the AD continuum, including MCI and dementia, suggesting that sex differences might be disease-stage dependent. Our results indicate that neurocognitive performance signatures built on data from digital biomarker features are different between men and women. These results stress the need to integrate traditional approaches to dementia research with digital biomarker technologies and personalized medicine perspectives to achieve more precise predictive diagnostics, targeted prevention, and customized treatment of cognitive decline.Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-022-00284-3.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ferrari, Alberto $u Women's Brain Project, Guntershausen, Switzerland $1 https://orcid.org/0000000259398637
700    1_
$a Meier, Irene B $u Chione GmbH, 8122 Binz, Switzerland
700    1_
$a Martinkova, Julie $u Women's Brain Project, Guntershausen, Switzerland $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Santus, Enrico $u Women's Brain Project, Guntershausen, Switzerland $u Bayer, NJ USA
700    1_
$a Marino, Nicola $u Women's Brain Project, Guntershausen, Switzerland $u Dipartimento Di Scienze Mediche E Chirurgiche, Università Degli Studi Di Foggia, Foggia, Italy
700    1_
$a Cirillo, Davide $u Women's Brain Project, Guntershausen, Switzerland $u Barcelona Supercomputing Center, Plaça Eusebi Güell, 1-3, 08034 Barcelona, Spain
700    1_
$a Mellino, Simona $u Women's Brain Project, Guntershausen, Switzerland
700    1_
$a Catuara Solarz, Silvina $u Women's Brain Project, Guntershausen, Switzerland
700    1_
$a Tarnanas, Ioannis $u Altoida Inc., Houston, TX USA $u Global Brain Health Institute, Dublin, Ireland
700    1_
$a Szoeke, Cassandra $u Women's Brain Project, Guntershausen, Switzerland $u Centre for Medical Research, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, Australia
700    1_
$a Hort, Jakub $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $u International Clinical Research Center, St Anne's University Hospital Brno, Brno, Czech Republic
700    1_
$a Valencia, Alfonso $u Barcelona Supercomputing Center, Plaça Eusebi Güell, 1-3, 08034 Barcelona, Spain $u ICREA - Institució Catalana de Recerca I Estudis Avançats, Pg. Lluís Companys 23, 08010 Barcelona, Spain
700    1_
$a Ferretti, Maria Teresa $u Women's Brain Project, Guntershausen, Switzerland
700    1_
$a Seixas, Azizi $u Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136 USA
700    1_
$a Santuccione Chadha, Antonella $u Women's Brain Project, Guntershausen, Switzerland
773    0_
$w MED00181668 $t The EPMA journal $x 1878-5077 $g Roč. 13, č. 2 (2022), s. 299-313
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35719134 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100049 $b ABA008
999    __
$a ind $b bmc $g 1816409 $s 1168257
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c 2 $d 299-313 $e 20220606 $i 1878-5077 $m The EPMA journal $n EPMA J $x MED00181668
LZP    __
$a Pubmed-20220718

Najít záznam

Citační ukazatele

Možnosti archivace